Research Paper on ArcticZymes R2D LigaseTM is published in the Biotechnology Journal
ArcticZymes Technologies ASA is pleased to announce the release of a research paper in the international peer-reviewed publication, Biotechnology Journal, showcasing the features and potential of the patent pending ArcticZymes R2D LigaseTM. This novel enzyme, introduced in 2021, has functionalities enabling innovative advancements in RNA analysis, diagnostics and synthesis.
Authored by Sigurd Gundesø et al., the recent publication entitled "R2D Ligase: Unveiling a Novel DNA Ligase with Surprising DNA-to-RNA Ligation Activity" describes the uniqueness of the ArcticZymes R2D LigaseTM and its specificity and ability to ligate and bridge DNA-to-RNA.
Through dissemination of our research findings in peer-reviewed journals, ArcticZymes aims to elevate awareness of our cutting-edge products and stimulate the emergence of disruptive technologies. We are committed to driving forward progress in the field, catalyzing innovation and paving the way for impactful scientific breakthroughs.
Michael Akoh, CEO comments: "We are happy to see the publication of our research paper on AZ R2D LigaseTM in the Biotechnology Journal. This marks a milestone for ArcticZymes and underscores the innovative potential of our ArcticZymes R2D LigaseTM. The insights shared in this publication highlight our commitment to advancing biotechnology and driving meaningful progress in the field of molecular biology. We are excited about the possibilities this enzyme presents and look forward to further contributing to discoveries in RNA diagnostics and synthesis."
Access the published article via this link: http://dx.doi.org/10.1002/biot.202300711
For more information, please contact:
ArcticZymes Technologies ASA
CEO, Michael B. Akoh
CFO, Børge Sørvoll
ir@arcticzymes.com
